180609-56-7

Basic information

• Product Name: Benzyl 2-methylpiperidine-1,2-dicarboxylate
• Synonyms: Benzyl 2-methylpiperidine-1,2-dicarboxylate;1,2-Piperidinedicarboxylic acid 2-methyl-1-(phenylmethyl)ester;1-benzyl 2-methyl piperidine-1,2-dicarboxylate
• CAS NO: 180609-56-7
• Molecular Formula: C₁₅H₁₉NO₄
• Molecular Weight: 277.32
• Mol File: 180609-56-7.mol

Chemical Properties

• Boiling Point: 390.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.187
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -3.33±0.40(Predicted)
• CAS DataBase Reference: Benzyl 2-methylpiperidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 2-methylpiperidine-1,2-dicarboxylate(180609-56-7)
• EPA Substance Registry System: Benzyl 2-methylpiperidine-1,2-dicarboxylate(180609-56-7)

Safety Data

• Hazardous Substances Data: 180609-56-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Benzyl 2-methylpiperidine-1,2-dicarboxylate is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the creation of a wide range of organic compounds.
Used in Pharmaceutical Production:
As a precursor in the production of pharmaceutical drugs, benzyl 2-methylpiperidine-1,2-dicarboxylate plays a crucial role in the synthesis of new medicinal compounds, potentially leading to the development of novel treatments for various health conditions.
Used in Medicinal Research:
Benzyl 2-methylpiperidine-1,2-dicarboxylate is studied for its potential medicinal properties, including its possible use as a treatment for conditions such as hypertension and neurological disorders, due to its unique chemical structure and reactivity.
Used in Research and Development:
In the pharmaceutical and chemical industries, benzyl 2-methylpiperidine-1,2-dicarboxylate is used as a research compound to explore its properties and potential applications, furthering scientific understanding and innovation in these fields.
It is important to handle benzyl 2-methylpiperidine-1,2-dicarboxylate with care due to its potentially hazardous properties, and it is typically stored under controlled conditions to ensure safety and stability.

Upstream product

• 501-53-1 benzyl chloroformate 
• 35677-83-9 methyl pipecolinate 
• 28697-07-6 N-benzyloxycarbonyl D/L-pipecolinic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 4043-87-2 pipecolic Acid 

Downstream Products

• 1359711-06-0 1,2-(4H)-pyridinedicarboxylic acid 5, 6-dihydro-2-methyl-1-(phenylmethyl) ester 
• 1350723-81-7 2-(3-methyl-5-oxy-4,5,6,7,8,9-hexahydro-3H-pyrazolo[3,4-c]isoquinolin-1-yl)piperdin-1-benzyl formate 
• 1350723-79-3 2-(1-methyl-4-cyclohexenyl-5-amino-1H-pyrazol-3-yl)piperidine-1-benzyl formate 
• 1350723-77-1 2-(1-methyl-5-amino-1H-pyrazol-3-yl)piperidine-1-benzyl formate 
• 105706-75-0 1-benzyloxycarbonyl-2-hydroxymethylpiperidine 

Relevant articles and documents

DERIVATIVES OF HETEROCYCLIC α-IMINOCARBOXYLIC ACIDS. 3. SYNTHESIS OF N-ALKOXYCARBONYL AND N-ALKOXYCARBONYLALKENYL DERIVATIVES OF α-IMINOCARBOXYLIC ACIDS.

By the interaction of L-proline, L-thioproline, pipecolic acid, tetrahydro-1,4-thiazine-3-carboxylic acid, and diastereomeric esters of tetrahydro-1,4-thiazine-3,5-dicarboxylic acid with methyl chloroformate, methyl propiolate, and acetylenecarboxylic aci

PROCESS FOR THE PRODUCTION OF COBIMETINIB

The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt content.

Formation of N-acyl-N,N'-dicyclohexylureas from DCC and arenecarboxylic acids in the presence of hydroxybenzotriazole in CH2CI2 at room temperature

The syntheses of N-acyl-N',N'-dicyclohexylureas from 1,3- dicyclohexylcarbodiimide and arenecarboxylic acids [p-XC6H 4CO2H (X = H or NO2), 2-, 3- or 4-pyridinecarboxylic acid and pyrazinecarboxylic acid] in the

1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of For

DERIVATIVES OF HETEROCYCLIC α-IMINOCARBOXYLIC ACIDS. 4. REDUCTION OF N-ALKOXYCARBONYL DERIVATIVES OF α-IMINOCARBOXYLIC ACIDS.

When N-methoxycarbonyl and N-benzoxycarbonyl derivatives of methyl esters of aziridine-2-carboxylic acid, L-proline, L-thioproline, and pipecolic acid interact with NaBH4 in tert-butanol/methanol, the products of reduction of the C-methoxycarbonyl group o